ReleaseWire Connect

RNCOS has recently launched “LG Electronics Inc. - Company Analysis”. The study provides an overview on company’s history, business, its mergers and acquisitions, etc. It covers profound information on the products and services offered by the company to make prospective clients aware about its product portfolio. It provides extensive financial information about the company to examine its financial health. Analytical tools like Ratio analysis have- been specifically designed to give an idea about the fundamentals of the company and will help analyze company’s position with respect to industry standards.

India is considered as one of the fastest growing pharmaceutical markets in the world. Export has been the key driver for the Indian pharmaceutical market. During the last few years, India has emerged as an intensely preferred manufacturing location of pharmaceuticals worldwide due to the low cost factor. The European and African countries have been added up as new destinations for exports. The exports are expected to pick up pace in future as healthcare reform in the US and other countries will inflate demand for generic drugs. As per our new research report “Booming Generics Drug Market in India”, the generic drugs market in India is projected to grow at a CAGR of around 16.3% during FY 2011-FY 2013 on account of rising exports.

The generics industry in Brazil has registered a significant growth rate during the last few years. Our research report “Brazil Generics Market Forecast to 2012”, says that the Brazilian generics market will continue to witness the same uptrend in next few years. It is expected that the generics market will post a CAGR of nearly 19% during 2010 - 2012. Our report has thoroughly examined the factors primarily responsible for growth of the generics industry. The biggest one among them is the strong government support that has made it a norm to prescribe generic in the public sector.

Indian clinical trial market projected to grow at a robust CAGR of around 29% during 2009-2013, says RNCOS in its new research report.

According to our latest report “Chile Food and Beverages Market Outlook to 2013” consumption patterns in Chile have undergone tremendous transformations during the past decade. For instance, people are shifting from locally produced staples to more expensive branded products, and are incorporating processed packaged foods in their diet chart. Improving health awareness will continue to bolster demand for “diet” and “light” foods and beverages. At the same time, consumption of convenience food is rising with increasing number of women joining the workforce and rising average working hours. With these shifts and other factors, the food and beverages retail sales is expected to reach US$ 26.5 billion in 2013.

RNCOS has recently launched “FuelCell Energy Inc. - Company Analysis”. The study provides an overview on company’s history, business, its mergers and acquisitions, etc.

According to our research report “Booming Egypt Telecom Market”, number of broadband users is expected to grow at a CAGR of around 30% during 2010-2013. As part of ICT development initiative, the Egyptian government is continuously adopting strategies to promote the usage of high-speed and low cost broadband Internet access among Egyptians. Besides, advancement of sectors such as, education & learning, medical & healthcare, governmental & public services, as well as industry development, trade and exports will provide boost to this segment.

Increasing health awareness and decreasing product prices will enable organic fruit and vegetable market to grow at 13% CAGR during 2010-2014, says RNCOS.

Backed by factors like increasing R&D and innovation, global protein therapeutics market is expected to grow at the CAGR of 12% during 2011-2013, RNCOS acknowledged.

As per our new research report “Global Monoclonal Antibody Market Analysis”, Europe is the second largest market for mAbs in the world. Our study indicates that ten major mAb products are commercially available in Europe, including Remicade, Zevalin, Campath, Herceptin, Rituxan, Simulect, Zenapax, Synagis, ReoPro, and the fully human Mab Humira. In fact, physicians are increasingly adopting mAbs because of its superior side effect profile in the European region.